Articles related to TYPE 2 DIABETES

New guidelines endorse the use of continuous glucose monitors and insulin pumps in hospital settings, potentially improving glycemic control while reducing hypoglycemia risk in noncritically ill patients.

SGLT-2 inhibitors offer benefits beyond glucose control, potentially addressing the systemic inflammatory components of metabolic diseases like diabetes, heart failure, and gout.

Patients taking semaglutide for diabetes were more than four times more likely to develop NAION compared to those on other diabetes medications, while those using it for obesity had a seven-fold increased risk.

Advancements in diabetes technology, including CGMs and smart insulin devices, are providing significant benefits in patient care, making it essential for clinicians to stay informed and comfortable with these innovations.

Regular examination and patient education on injection-site rotation are crucial in preventing insulin-induced lipohypertrophy and maintaining effective glycemic control.

Hypomagnesemia, prevalent in patients with type 2 diabetes and those in intensive care, is often underdiagnosed due to nonspecific symptoms and lack of routine serum magnesium measurements.